Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir  

作　　者：Yu Bai Fei Ye Yong Feng Hanyi Liao Hao Song Jianxun Qi George Fu Gao Wenjie Tan Lifeng Fu Yi Shi 

机构地区：[1]Savaid Medical School,University of Chinese Academy of Sciences,Beijing 100049,China [2]CAS Key Laboratory of Pathogenic Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China [3]NHC Key Laboratory of Biosafety,National Institute for Viral Disease Control&Prevention,Chinese Center for Disease Control and Prevention,China CDC,Beijing 102206,China [4]Research Network of Immunity and Health(RNIH),Beijing Institutes of Life Science,Chinese Academy of Sciences,Beijing 100101,China [5]Center for Influenza Research and Early Warning(CASCIRE),CAS-TWAS Center of Excellence for Emerging Infectious Disease(CEEID),Chinese Academy of Sciences,Beijing 100101,China

出　　处：《Signal Transduction and Targeted Therapy》2021年第3期584-586,共3页信号转导与靶向治疗（英文）

基　　金：This work was supported by the Strategic Priority Research Program of CAS(XDB29010000);the National Science and Technology Major Project(2018ZX10101004 and 2018ZX10733403);the National Key Research and Development Program of China(2020YFC0845900,2016YFD0500300 and 2016YFE0205800);the National Natural Science Foundation of China(82041016,81871658,81673358 and 21807109);a grant from the Bill&Melinda Gates Foundation and and is partially supported by the Yanqi Lake Meeting organized by the Academic Divisions of CAS;Y.S.is supported by the Youth Innovation Promotion Association of CAS.

摘　　要：Dear Editor,The second wave of the coronavirus disease(COVID-19)pandemic has recently appeared in Europe.Most European countries,such as France,Germany,and Italy,have announced the implementation of a new round of epidemic prevention and control measures.However,no clinical drug or vaccine has been approved for the treatment of COVID-19.The interim results of the solidarity therapy trial coordinated by the World Health Organization(WHO)indicated that remdesivir,hydroxychloroquine,lopina-vir/ritonavir,and interferon appear to have little or no effect on the 28-day mortality of hospitalized patients or the hospitalization process of new COVID-19 patients.Therefore,there is an urgent need to develop new drugs against COVID-19.

关 键 词：PREVENTION DRUG DRUGS 

分 类 号：R373[医药卫生—病原生物学]